Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -3.73 | Insider Own | 3.83% | Shs Outstand | 51.46M | Perf Week | -9.55% |
| Market Cap | 11.22B | Forward P/E | 41.45 | EPS next Y | 5.26 | Insider Trans | -13.03% | Shs Float | 43.56M | Perf Month | -9.42% |
| Enterprise Value | 11.13B | PEG | - | EPS next Q | - | Inst Own | 76.21% | Short Float | 6.94% | Perf Quarter | 4.93% |
| Income | -189.58M | P/S | 15.84 | EPS this Y | 38.33% | Inst Trans | - | Short Ratio | 3.28 | Perf Half Y | 17.66% |
| Sales | 708.24M | P/B | - | EPS next Y | 328.63% | ROA | -26.39% | Short Interest | 3.02M | Perf YTD | 19.36% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -260.01% | 52W High | 251.90 -16.22% | Perf Year | 115.28% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -50.29% | 52W Low | 93.03 126.86% | Perf 3Y | 186.08% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 133.68% - | Gross Margin | 92.60% | Volatility | 4.78% 4.21% | Perf 5Y | 306.09% |
| Dividend TTM | - | EV/Sales | 15.72 | EPS Y/Y TTM | 37.73% | Oper. Margin | -24.80% | ATR (14) | 10.00 | Perf 10Y | 2645.47% |
| Dividend Ex-Date | - | Quick Ratio | 1.32 | Sales Y/Y TTM | 83.42% | Profit Margin | -26.59% | RSI (14) | 38.24 | Recom | 2.04 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.39 | EPS Q/Q | -57.50% | SMA20 | -7.67% | Beta | 0.64 | Target Price | 265.29 |
| Payout | 0.00% | Debt/Eq | 4.03 | Sales Q/Q | 57.85% | SMA50 | -8.64% | Rel Volume | 0.87 | Prev Close | 217.99 |
| Employees | 1,220 | LT Debt/Eq | 1.91 | Earnings | Aug 10 | SMA200 | 17.70% | Avg Volume | 896.61K | Price | 211.04 |
| IPO Date | Nov 19, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -49.21% -0.79% | Net Debt/EBITDA | 0.49 | Volume | 781,854 | Change | -3.19% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-20-26 | Initiated | BMO Capital | Outperform | $310 |
| Jul-07-26 | Reiterated | RBC Capital | Outperform | $302 → $304 |
| Jun-11-26 | Reiterated | Jefferies | Buy | $275 → $380 |
| May-05-26 | Reiterated | Deutsche Bank | $281 → $280 | |
| May-05-26 | Reiterated | Robert W. Baird | $241 → $246 | |
| May-05-26 | Reiterated | Morgan Stanley | Equal Weight | $217 → $242 |
| May-05-26 | Reiterated | Needham | Buy | $225 → $267 |
| May-05-26 | Reiterated | HC Wainwright & Co. | Buy | $270 → $290 |
| May-05-26 | Reiterated | RBC Capital | Outperform | $222 → $302 |
| May-04-26 | Reiterated | Oppenheimer | $250 → $280 |
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 708 | 638 | 386 | 271 | 50 | 0 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 52 | 47 | 33 | 26 | 5 | 0 | 0 | 0 | 0 | |
| Gross Profit | 656 | 591 | 352 | 245 | 45 | 0 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 634 | 571 | 411 | 323 | 159 | 67 | 29 | 14 | 9 | |
| Research and Development | 192 | 183 | 187 | 98 | 58 | 58 | 70 | 54 | 23 | |
| Other Operating Expense | 5 | 6 | 35 | 55 | 8 | 0 | 0 | -1 | 1 | |
| Operating Income | -175 | -169 | -281 | -232 | -180 | -125 | -99 | -67 | -33 | |
| Interest Expense | 5 | 7 | 7 | 6 | 7 | 6 | 3 | 1 | 1 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -8 | -8 | 0 | 0 | 0 | 0 | -1 | 0 | 3 | |
| Net Income Before Taxes | -189 | -184 | -287 | -238 | -187 | -130 | -103 | -68 | -31 | |
| Income Taxes | -1 | -1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -189 | -183 | -287 | -239 | -187 | -130 | -103 | -68 | -31 | |
| Net Income From Continuing Operations | -189 | -183 | -287 | -239 | -187 | -130 | -103 | -68 | -31 | |
| Net Income | -189 | -183 | -287 | -239 | -187 | -130 | -103 | -68 | -31 | |
| EPS (Recurring) | -3.73 | -3.68 | -5.99 | -5.27 | -4.60 | -3.47 | -2.83 | -2.05 | -1.15 | |
| EPS (Basic, Before Extraordinaries) | -3.73 | -3.68 | -5.99 | -5.27 | -4.60 | -3.47 | -2.83 | -2.05 | -1.15 | |
| EPS (Diluted) | -3.73 | -3.68 | -5.99 | -5.27 | -4.60 | -3.47 | -2.83 | -2.05 | -1.15 | |
| EBITDA | -173 | -168 | -273 | -225 | -175 | -125 | -100 | -67 | -33 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 15.20 | 14.31 | 10.52 | 13.22 | 63.25 | — | — | — | — | |
| Gross Margin | 92.66 | 92.63 | 91.19 | 90.41 | 90.00 | — | — | — | — | |
| Operating Margin | -24.72 | -26.49 | -72.80 | -85.61 | -360.00 | — | — | — | — | |
| Net Margin | -26.69 | -28.68 | -74.35 | -88.19 | -374.00 | — | — | — | — | |
| Shares Outstanding | 51 | 50 | 48 | 45 | 41 | 38 | 37 | 34 | 27 | |
| Market Capitalization | 10,763 | 9,132 | 4,061 | 3,582 | 3,162 | 1,436 | 3,014 | 3,514 | 76 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT | Chief Executive Officer | Jul 01 '26 | Sale | 240.25 | 49,666 | 11,932,257 | 7,229 | Jul 01 |
| TABUTEAU HERRIOT | Chief Executive Officer | Jul 01 '26 | Option Exercise | 4.95 | 49,666 | 245,847 | 56,895 | Jul 01 |
| JEFFS ROGER | Director | Jun 11 '26 | Sale | 249.12 | 286 | 71,248 | 58,367 | Jun 11 |
| JEFFS ROGER | Director | Jun 10 '26 | Sale | 246.18 | 286 | 70,407 | 58,653 | Jun 11 |
| Coleman Mark | Director | Jun 10 '26 | Sale | 249.00 | 643 | 160,107 | 30,389 | Jun 10 |
| Mahony Susan | Director | Jun 10 '26 | Sale | 246.18 | 300 | 73,854 | 829 | Jun 10 |
| Mahony Susan | Director | Jun 09 '26 | Sale | 237.21 | 300 | 71,163 | 1,129 | Jun 10 |
| Coleman Mark | Director | Jun 08 '26 | Option Exercise | 0.00 | 1,429 | 0 | 31,032 | Jun 10 |
| JEFFS ROGER | Director | Jun 08 '26 | Option Exercise | 0.00 | 1,429 | 0 | 58,939 | Jun 10 |
| Saad Mark E | Director | Jun 08 '26 | Option Exercise | 0.00 | 1,429 | 0 | 11,431 | Jun 10 |
| Mahony Susan | Director | Jun 08 '26 | Option Exercise | 0.00 | 1,429 | 0 | 1,429 | Jun 10 |
| Pizzie Nick | Chief Financial Officer | Jun 09 '26 | Option Exercise | 3.50 | 33,000 | 115,500 | 75,867 | Jun 09 |
| Pizzie Nick | Chief Financial Officer | Jun 09 '26 | Sale | 240.09 | 33,000 | 7,922,970 | 42,867 | Jun 09 |
| TABUTEAU HERRIOT | Chief Executive Officer | Jun 09 '26 | Option Exercise | 4.95 | 49,670 | 245,867 | 56,899 | Jun 09 |
| TABUTEAU HERRIOT | Chief Executive Officer | Jun 09 '26 | Sale | 241.01 | 49,670 | 11,970,967 | 7,229 | Jun 09 |